On the first of July the U.S. Department of Health ordered an additional 2.5 million doses of Bavarian Nordic's JYNNEOS for use in responding to current or future monkeypox outbreaks and as part of U.S. outbrak preparedness.
The order announced last week in addition to the 500,000 doses of government-owned vaccine the company is producing in 2022 for use in the current response to monkeypox in the U.S and brings the total vaccine doses to be delivered in 2022 and 2023 to more than 4 million.
Two vaccines licensed by the U.S. Food and Drug Administration (FDA) are available for preventing monkeypox infection – JYNNEOS (also known as Imvamune or Imvanex) and ACAM2000.
Read more about the monkeypox vaccines.
The U.S. government is ramping up its efforts to fight monkeypox by sending hundreds of thousands of vaccine doses to states in the coming months, expanding access for those most at risk and increasing supply to areas with high case numbers.
Monkeypox outbreak at a glance
Since 1 January and as of 6 July 2022, 7243 confirmed cases and one death have been reported to WHO from 54countries. Monkeypox is found mainly in Central and West Africa, often in tropical forested areas, although monkeypox has also spread in cities.
Currently there is an outbreak in non-African countries, and many patients affected have been men who had close social or intimate (including sexual) contact with men.
What are the current groups eligible for vaccine?
The vaccine is recommended only for groups who are at higher risk of developing monkeypox.
If you've had significant contact with someone with confirmed monkeypox, you may be offered the vaccine.
The vaccine may also be recommended for some people before they come into contact with monkeypox.